Lonza to make cancer drug for Micromet

Published: 25-Nov-2009 Featured companies: Lonza
Ingredients Regulatory Research & Development Pharmaceutical

Swiss biopharmaceuticals group Lonza has agreed to manufacture Micromet's blinatumomab (MT103), a drug used to treat various haematologic cancers.


Swiss biopharmaceuticals group Lonza has agreed to manufacture Micromet's blinatumomab (MT103), a drug used to treat various haematologic cancers.

Micromet is a US biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases.

Lonza says it will manufacture blinatumomab for clinical trials, develop the commercial scale process and supply the drug for the market if requested.

Blinatomumab has achieved the primary endpoint in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia and has shown success in an ongoing phase I trial for the treatment of patients with non-Hodgkin's lymphoma.

Featured companies

At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of around 17,500 skilled employees work across a...
See more

You may also like

Research & Development

Overcome challenges and secure successful technology transfers of complex biological products in sterile manufacturing

Read more
The biopharmaceutical industry has seen many challenges in the last few years, spawned not just by a global pandemic but also the industry-wide disruption of operational and supply chain strategies that emerged in its aftermath...

Trending Articles

  1. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  2. Fasenra for EGPA: addressing unmet needs Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  5. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology

Relevant companies

See more

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Research & Development

Overcome challenges and secure successful technology transfers of complex biological products in sterile manufacturing

The biopharmaceutical industry has seen many challenges in the last few years, spawned not just by a global pandemic but also the industry-wide disruption of operational and supply chain strategies that emerged in its aftermath...
Research & Development

Lonza launches GS Effex cell line to develop therapeutic antibodies with increased potency

The new cell line is designed to help overcome challenges in immunotherapy research and development related to the need for antibody therapeutics to have increased potency
Research & Development

Accelerating early stage small molecule drug development

Although drug discovery and development is a complex process, there are many ways that improvements can be made. Three of the issues facing drug developers — poor solubility, predicting pharmacokinetics and synthetic route selection — can all be addressed in advance to make the whole process run more effectively
Manufacturing

How to get a competitive edge in pharmaceutical development

Lonza is set to provide insights on challenges around enteric delivery and how they can greatly support your next development project in a webinar on 3 October
Manufacturing

Addressing challenges with clinical in-use testing of biotherapeutics

In this article, Lonza discusses the more demanding aspects surrounding clinical in-use testing of biotherapeutic DPs for parenteral delivery while reviewing potential strategies to address these issue
Manufacturing

Lonza and Vertex open transformative cell therapy facility

The companies have opened a manufacturing facility in Portsmouth, New Hampshire, to accelerate the development of cell therapies for type 1 diabetes
Manufacturing

Lonza launches media system to aid therapeutic protein manufacture

The launch supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time-to-market
Subscribe now